A Phase 1/2 interventional study of NPC-08 in Malignant Glioma, sponsored by Nobelpharma. Completed at 1 site in Japan. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2013-10-30.
Sponsored by Nobelpharma · Phase 1/2, Interventional, and Treatment
The purpose of this study is to evaluate whether NPC-08 is safety and efficacy in the treatment of newly-diagnosed malignant glioma and recurrent glioblastoma multiforme.
1,920 studies on the registry are indexed under Glioblastoma; 449 are open to participants now.
This study's enrollment of 24 is below the median of 36 across 1,617 interventional studies indexed under Glioblastoma.
Browse Glioblastoma studies →Nobelpharma is the lead sponsor of 34 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: NPC-08
Polifeprosan 20 with Carmustine 3.85%
Overall survival to 12 months
Time frame: 12 months
Progression-free survival
Time frame: 12 months
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nobelpharma